Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats

Treatment with metformin, the biguanide of hepatic insulin sensitizer, in patients with non-alcoholic fatty liver disease (NAFLD) has been reported with contradictory findings regarding the effectiveness on bl...
Source: Diabetology and Metabolic Syndrome - Category: Endocrinology Authors: Tags: Research Source Type: research

Related Links:

Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH.
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Authors: Klujszo EH, Parcheta P, Witkowska AB, Krecisz B Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the western countries. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing a more severe form of the disease with poorer outcomes. The components of the metabolic syndrome - obesity, lipid abnormalities, hypertension, and type 2 diabetes - significantly correlate with NAFLD progression. The inflammatory state present in psoriasis plays a significant role in development of NAFLD and the metabolic syndrome. All patients with psoriasis a...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. Therefore, we sought to determine the most important predictors of NAFLD among middle ‑aged men and women in Isfahan, Iran.Methods: A total of 413 individuals (163 men and 250 women) aged 30 –60 years were selected by stratified random sampling. The participants had safe alcohol consumption habits (
Source: International Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
ConclusionsThe prevalence of NAFLD is high in women with prior GDM. Such women also have a high burden of cardiometabolic risk factors. Future studies should evaluate the intermediate and long ‐term hepatic and cardiovascular risk and the impact of lifestyle interventions in reducing morbidity in such women.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Non-alcoholic Fatty Liver Disease (NAFLD) is the leading cause of liver disease worldwide with rising rates in parallel to those of obesity, type 2 diabetes and metabolic syndrome. NAFLD encompasses a wide spectrum of pathology from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis, which are linked to poor outcomes. Studies confirm a significant amount of undiagnosed NAFLD and related fibrosis within the community increasing the overall burden of the disease. NAFLD appears to be more prevalent in certain populations such as those with type 2 diabetes and metabolic syndrome.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Review Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and represent a common finding in highly prevalent metabolic disorders (i.e. type 2 diabetes, metabolic syndrome, obesity). Non-alcoholic steatohepatitis (NASH) requires liver biopsy for grading and staging the liver damage by the assessment of steatosis, inflammation and fibrosis.In parallel with the development of numerous ‘liquid’ biomarkers and algorithms that combine anthropometric and laboratory parameters, innovative hepatic imaging techniques have increasingly been developed to attempt to overcome the need for biopsy, b...
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Tags: Review Source Type: research
With the increasing prevalence of obesity, obesity-related problems such as cardiometabolic disorders (CMD), are also rapidly increasing. To prevent and alleviate the progressive course of CMD, it is important to discover the pathophysiological mechanisms between obesity and CMD. Adipose tissue is now recognized as an active endocrine organ that releases adipokines. Adipokines play a pivotal role in chronic low-grade inflammation, oxidative stress, and impaired insulin signaling, contributing to metabolic derangement and leading to CMD. Recent studies have provided substantial evidence supporting the association between ad...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Nutritional status is often impaired in people with chronic liver disease. The degree of malnutrition increases with increasing hepatic decompensation and has a significant effect on morbidity and mortality, mainly in those patients with refractory ascites, multiple hospitalizations, cholestatic cirrhosis or chronic persistent alcohol abuse.1 Nevertheless, with the increasing prevalence of obesity, diabetes and metabolic syndrome some patients with cirrhosis may appear overweight or obese despite being malnourished, especially in the setting of non-alcoholic fatty liver disease (NAFLD).
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Hepatology Snapshot Source Type: research
More News: Alcoholism | Diabetes | Endocrinology | Fatty Liver Disease (FLD) | Fortamet | Insulin | Liver | Liver Disease | Metabolic Syndrome | Metformin | Non-alcoholic Fatty Liver Diseases (NAFLD) | Urology & Nephrology